International Journal of Molecular Sciences · 2018 · 80 citations · 34 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyImmunotherapyCancer ImmunotherapyCell-based ImmunotherapyChimeric Antigen Receptor T-cell TherapyNatural Killer Cell BiologyNatural Killer Cell FunctionNatural Killer Cell TherapyCar Natural Killer Cell TherapyCar-nk Cell TherapyChimeric Antigen Receptor Natural Killer CellsNatural Killer Cell-based Cancer ImmunotherapyPeripheral Blood Natural Killer CellsT Cell CytotoxicityT Cell ReceptorsTargeted Transfection
Natural killer T (NKT) cells represent a cell subpopulation that combines characteristics of natural killer (NK) cells and T cells. Through their endogenous T-cell receptors (TCRs), they reveal a pronounced intrinsic anti-tumor activity. Thus, a NKT cell transfected with a chimeric antigen receptor (CAR), which recognizes a tumor-specific surface antigen, could attack tumor cells antigen-specifically via the CAR and additionally through its endogenous TCR. NKT cells were isolated from peripheral blood mononuclear cells (PBMCs), expanded, and electroporated with mRNA encoding a chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR. The CAR expression on NKT cells and their in vitro functionality were analyzed. A transfection efficiency of more than 80% was achieved. Upon stimulation with melanoma cells, CAR-NKT cells produced cytokines antigen-specifically. Compared with conventional CAR-T cells, cytokine secretion of CAR-NKT cells was generally lower. Specific cytotoxicity, however, was similar with CAR-NKT cells showing a trend towards improved cytotoxicity. Additionally, CAR-NKT cells could kill target cells through their endogenous TCRs. In summary, it is feasible to generate CAR-NKT cells by using mRNA electroporation. Their CAR-mediated cytotoxicity is at least equal to that of conventional CAR-T cells, while their intrinsic cytotoxic activity is maintained. Thus, CAR-NKT cells may represent a valuable alternative to conventional CAR-T cells for cancer immunotherapy.
34
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text
Medicine, Hematology, Oncology +16
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park, Isabelle Rivière, Mithat Gönen et al. · New England Journal of Medicine · 2018 · 2.7K citations · Full text
Life Sciences, Hematology, Oncology +17
CD1d-Restricted and TCR-Mediated Activation of V <sub>α</sub> 14 NKT Cells by Glycosylceramides
Tetsu Kawano, Junqing Cui, Yasuhiko Koezuka et al. · Science · 1997 · 2.4K citations